CB-86
Synthetic resorcinol-anandamide hybrid, ligand of the CB1 and CB2 receptors, for research use.
C₂₆H₄₃NO₃
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- N-cyclopropyl-8-[3-hydroxy-5-(2-methyloctan-2-yl)phenoxy]octanamide
- Other names
- NS00017572
Identifiers
- Formula
- C₂₆H₄₃NO₃
- Molar mass
- 417.60 g/mol
- PubChem CID
- 42625202(new tab)
- InChIKey
- PVAOGZXUOOHSMN-UHFFFAOYSA-N
Class
- Family
- ECS modulator (research)
Updated on
Receptors and activity
- CB1ModulatorKi 5,6 nM (Brizzi et coll., 2009)88 out of 100
- CB2ModulatorKi 7,9 nM (Brizzi et coll., 2009)85 out of 100
Subjective signature
- Calm
- 8 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 2 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 2 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 2 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 3 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
CB-86 is a synthetic resorcinol-anandamide hybrid, described in 2009 by Brizzi et al. in the Journal of Medicinal Chemistry. The published measurements report an inhibition constant of 5.6 nM at CB1 and 7.9 nM at CB2, on human receptors expressed in COS cells. The summary of the study reports in vivo antinociceptive activity for the series. No human data have been found, and its documented use is research.
Key sources.
- Brizzi et coll., hybrides résorcinol-anandamide comme ligands puissants des récepteurs cannabinoïdes, J Med Chem 2009 (new tab)PMID 19331413
- ChEMBL, molécule CHEMBL490648 (affinités CB1 et CB2, document CHEMBL1153817) (new tab)
- PubChem, notice du composé CB-86 (CID 42625202) (new tab)
- ANSM, liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026) (new tab)
- INCB, Green List 2026 (conventions de 1961 et 1971) (new tab)
History
- Source
- Synthetic molecule. No plant source is documented for this compound in the sources consulted. It belongs to the series of resorcinol-anandamide hybrids, designed from the pharmacophoric requirements of THC and anandamide.
Origin (research tool)
No biosynthetic pathway: the molecule is obtained by chemical synthesis. Class of synthesis: an ether of a resorcinol bearing a 2-methyloctan-2-yl group, linked to an N-cyclopropyl amide by a carbon chain.
Legal framework
- European Union
No harmonised control measure at European Union level was found for this molecule in the sources consulted: any control falls, where it exists, under the national law of each Member State.
- France
CB-86 is not named in any annex of the decree of 22 February 1990, nor in the ANSM consolidated list (update of 16 February 2026). It is not a tetrahydrocannabinol, nor an ester, ether or salt of one (the 'Tetrahydrocannabinols' entry of the list), and it has no benzo[c]chromene core (clause of 22 May 2024). It has no cyclohexylphenol core (2-(3-hydroxycyclohexyl)phenol), no indole or indazole ring and no naphthoyl group, so it cannot be attached to any of the generic family definitions in the list. It is therefore unscheduled in France. This status is not an authorisation.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Brizzi et coll., hybrides résorcinol-anandamide comme ligands puissants des récepteurs cannabinoïdes, J Med Chem 2009 (new tab)PMID 19331413
- ChEMBL, molécule CHEMBL490648 (affinités CB1 et CB2, document CHEMBL1153817) (new tab)
- PubChem, notice du composé CB-86 (CID 42625202) (new tab)
- ANSM, liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026) (new tab)
- INCB, Green List 2026 (conventions de 1961 et 1971) (new tab)
Structured data
- SMILES
- CCCCCCC(C)(C)C1=CC(=CC(=C1)OCCCCCCCC(=O)NC2CC2)O
- InChIKey
- PVAOGZXUOOHSMN-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.